BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug
Dec 11 (Reuters) - Agios Pharmaceuticals Inc:
* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION
* FIRST EXPANSION DATA, UPDATED DOSE-ESCALATION DATA SHOW OVERALL EFFICACY, SAFETY PROFILE FOR IVOSIDENIB CONSISTENT WITH PREVIOUS DATA
* FIRST EXPANSION DATA, UPDATED DOSE-ESCALATION DATA SUPPORT IVOSIDENIB NDA SUBMISSION FOR IDH1M R/R AML BY YEAR END 2017 Source text for Eikon: Further company coverage: